ES2421731T3 - Composición y procedimiento para el tratamiento de MRSA - Google Patents

Composición y procedimiento para el tratamiento de MRSA

Info

Publication number
ES2421731T3
ES2421731T3 ES09790912T ES09790912T ES2421731T3 ES 2421731 T3 ES2421731 T3 ES 2421731T3 ES 09790912 T ES09790912 T ES 09790912T ES 09790912 T ES09790912 T ES 09790912T ES 2421731 T3 ES2421731 T3 ES 2421731T3
Authority
ES
Spain
Prior art keywords
composition
treatment
mrsa
procedure
chlorhexidine digluconate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09790912T
Other languages
English (en)
Inventor
Cale Street
Nicolas Loebel
Lisa Pedigo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ondine International Ltd
Original Assignee
Ondine International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ondine International Ltd filed Critical Ondine International Ltd
Application granted granted Critical
Publication of ES2421731T3 publication Critical patent/ES2421731T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Una composición adecuada para reducir microbios que causan enfermedades que comprende:un fotosensibilizador; digluconato de clorhexidina, siendo la concentración del digluconato de clorhexidina superior a un 0,01% e inferior a un 2% v/v; y un vehículo farmacéuticamente aceptable; estando destinada la composición a la desinfección fotodinámica de un sitio de tratamiento que contiene losmicrobios.
ES09790912T 2008-08-01 2009-07-29 Composición y procedimiento para el tratamiento de MRSA Active ES2421731T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8557708P 2008-08-01 2008-08-01
US18606809P 2009-06-11 2009-06-11
PCT/US2009/052059 WO2010014676A1 (en) 2008-08-01 2009-07-29 Composition and method for treatment of mrsa

Publications (1)

Publication Number Publication Date
ES2421731T3 true ES2421731T3 (es) 2013-09-05

Family

ID=41277515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09790912T Active ES2421731T3 (es) 2008-08-01 2009-07-29 Composición y procedimiento para el tratamiento de MRSA

Country Status (12)

Country Link
US (2) US8247406B2 (es)
EP (1) EP2323643B1 (es)
JP (1) JP2011529898A (es)
KR (1) KR101631335B1 (es)
CN (1) CN102112120B (es)
AU (1) AU2009276679B2 (es)
CA (1) CA2732307C (es)
ES (1) ES2421731T3 (es)
GB (1) GB2475005A (es)
HK (1) HK1158522A1 (es)
IL (1) IL210997A (es)
WO (1) WO2010014676A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101631335B1 (ko) 2008-08-01 2016-06-16 온딘 인터내셔널 리미티드. Ｍｒｓａ 치료용 조성물 및 방법
JP5651426B2 (ja) * 2010-10-25 2015-01-14 阪田　功 クロリン誘導体
EP2654806B1 (en) * 2010-12-22 2019-05-22 Ortner Cleanroom Engineering GmbH Photodynamic control of microbial growth on surfaces
EP2710085B1 (en) 2011-05-16 2018-09-26 Avery Dennison Corporation Adhesive containing microparticles
WO2013074628A1 (en) * 2011-11-17 2013-05-23 Avery Dennison Corporation Controlled release of active using ph
US11497932B2 (en) 2012-04-05 2022-11-15 Light Line Medical, Inc. Electromagnetic radiation delivery and monitoring system and methods for preventing, reducing and/or eliminating catheter-related infections during institutional or in-home use
MX2015010327A (es) 2013-02-07 2016-06-07 Avery Dennison Corp Adhesivos antimicrobianos que tienen propiedades mejoradas .
WO2014151355A1 (en) 2013-03-15 2014-09-25 Avery Dennison Corporation Transparent cover dressing application system and inclusion of label strip
WO2015089421A1 (en) 2013-12-12 2015-06-18 Innovation Technologies, Inc. Materials and methods for controlling infections
US10016375B2 (en) 2013-12-12 2018-07-10 Paul J. Rucinski Materials and methods for controlling infections
EP3151813B1 (en) 2014-06-05 2020-12-09 Avery Dennison Corporation Articles with active agent concentrated at the substrate contacting surface and related methods
US11479799B2 (en) 2014-09-16 2022-10-25 President And Fellows Of Harvard College Engineered water nanostructures (EWNS) and uses thereof
JP6602400B2 (ja) * 2016-02-04 2019-11-06 富士フイルム株式会社 光線力学療法用組成物、殺菌システムおよび殺菌システムの作動方法
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
WO2020246350A1 (ja) * 2019-06-03 2020-12-10 学校法人慈恵大学 殺菌剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN066795A0 (en) 1995-01-20 1995-02-16 Macquarie Research Limited Method of repair
US20020022660A1 (en) * 1998-01-20 2002-02-21 Hanuman B. Jampani Deep penetrating antimicrobial compositions
US6607522B1 (en) 2000-03-16 2003-08-19 General Hospital Corporation Methods for tissue welding using laser-activated protein solders
GB0023367D0 (en) 2000-09-23 2000-11-08 Univ Leeds Photosensitisers
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
WO2008070023A2 (en) * 2006-12-01 2008-06-12 Pond Gary J Improved dental irrigant
US20090093470A1 (en) * 2007-10-08 2009-04-09 Ondine International, Ltd. Photodynamic therapy process and photosensitizer compositions therefor
KR101631335B1 (ko) 2008-08-01 2016-06-16 온딘 인터내셔널 리미티드. Ｍｒｓａ 치료용 조성물 및 방법

Also Published As

Publication number Publication date
HK1158522A1 (en) 2012-07-20
AU2009276679A1 (en) 2010-02-04
US20100029779A1 (en) 2010-02-04
US8618091B2 (en) 2013-12-31
CN102112120B (zh) 2013-01-23
CN102112120A (zh) 2011-06-29
JP2011529898A (ja) 2011-12-15
KR20110055523A (ko) 2011-05-25
IL210997A (en) 2016-05-31
EP2323643B1 (en) 2013-05-08
KR101631335B1 (ko) 2016-06-16
US8247406B2 (en) 2012-08-21
AU2009276679A2 (en) 2011-02-03
GB2475005A (en) 2011-05-04
GB201103465D0 (en) 2011-04-13
US20120277660A1 (en) 2012-11-01
IL210997A0 (en) 2011-04-28
WO2010014676A1 (en) 2010-02-04
AU2009276679B2 (en) 2013-05-16
CA2732307C (en) 2017-01-24
EP2323643A1 (en) 2011-05-25
CA2732307A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ES2421731T3 (es) Composición y procedimiento para el tratamiento de MRSA
EA201200143A1 (ru) Антибактериальная композиция для ротовой полости
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
UY29876A1 (es) Derivados de acidos dicarboxilicos y su uso
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
EP2452935A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
EA201200253A1 (ru) Композиция для лечения муковисцидоза
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
PA8850801A1 (es) Compuestos útiles para inhibir chk1
GT200500063A (es) Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
CL2009000009A1 (es) Kit biocida para aplicaciones agricolas que comprende una dosis de una solucion basica de hipoclorito y una dosis de una resina de intercambio cationico como agente regulador del ph, de manera que una vez mezcladas dichas dos dosis, el ph queda entre 5 y 8; metodo para tratamiento biocidas que comprende el uso de dicho kit.
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno